Business Description
Purple Biotech Ltd
ISIN : US74638P1093
Share Class Description:
FRA:1YI: ADRCompare
Compare
Traded in other countries / regions
PPBT.IsraelPPBT.USA1YI.Germany IPO Date
2019-02-11Description
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.34 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.8 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | -33.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.61 | |||||
| 9-Day RSI | 42.48 | |||||
| 14-Day RSI | 44.96 | |||||
| 6-1 Month Momentum % | -31.08 | |||||
| 12-1 Month Momentum % | -69.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 1.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -32.84 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.61 | |||||
| ROA % | -37.54 | |||||
| ROIC % | -67.4 | |||||
| 3-Year ROIIC % | -227.28 | |||||
| ROC (Joel Greenblatt) % | -3485.44 | |||||
| ROCE % | -44.99 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.16 | |||||
| Price-to-Tangible-Book | 2.65 | |||||
| EV-to-EBIT | 0.17 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.17 | |||||
| EV-to-FCF | 0.15 | |||||
| Price-to-Net-Current-Asset-Value | 5.32 | |||||
| Price-to-Net-Cash | 5.32 | |||||
| Earnings Yield (Greenblatt) % | 598.15 | |||||
| FCF Yield % | -399.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Purple Biotech Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -11.859 | ||
| Beta | 0.57 | ||
| Volatility % | 105.08 | ||
| 14-Day RSI | 44.96 | ||
| 14-Day ATR (€) | 0.021655 | ||
| 20-Day SMA (€) | 6.12 | ||
| 12-1 Month Momentum % | -69.4 | ||
| 52-Week Range (€) | 5.44 - 19.7 | ||
| Shares Outstanding (Mil) | 1.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Purple Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Purple Biotech Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Purple Biotech Ltd Frequently Asked Questions
What is Purple Biotech Ltd(FRA:1YI)'s stock price today?
The current price of FRA:1YI is €6.12. The 52 week high of FRA:1YI is €19.70 and 52 week low is €5.44.
When is next earnings date of Purple Biotech Ltd(FRA:1YI)?
The next earnings date of Purple Biotech Ltd(FRA:1YI) is 2025-02-08 Est..
Does Purple Biotech Ltd(FRA:1YI) pay dividends? If so, how much?
Purple Biotech Ltd(FRA:1YI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers